ANI Pharmaceuticals, Inc. (ANIP) Sets New 52-Week High at $74.33

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $74.33 and last traded at $63.35, with a volume of 83800 shares traded. The stock had previously closed at $63.73.

Several analysts have issued reports on the stock. TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Tuesday, November 7th. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $68.25.

The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. The stock has a market cap of $738.22, a P/E ratio of 18.91 and a beta of 2.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. During the same quarter in the previous year, the firm posted $1.09 earnings per share. The company’s revenue was up 25.0% on a year-over-year basis. research analysts predict that ANI Pharmaceuticals, Inc. will post 3.59 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 664 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of ANI Pharmaceuticals by 132.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 2,390 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter valued at approximately $197,000. Stevens Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $207,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $210,000. 57.66% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Sets New 52-Week High at $74.33” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/11/24/ani-pharmaceuticals-inc-anip-sets-new-52-week-high-at-74-33.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply